SELEGILINE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for selegiline and what is the scope of freedom to operate?

Selegiline is the generic ingredient in four branded drugs marketed by Somerset, Norvium Bioscience, Apotex, Lannett Co Inc, Novitium Pharma, Rising, Bausch, Apotex Inc, Chartwell Molecules, Cosette, Dash Pharms Natco, G And W Labs Inc, Kenton, and MLV, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for selegiline. One supplier is listed for this compound.

Summary for SELEGILINE

US Patents:	0
Tradenames:	4
Applicants:	14
NDAs:	17
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	38
Patent Applications:	7,807
Drug Prices:	Drug price trends for SELEGILINE
What excipients (inactive ingredients) are in SELEGILINE?	SELEGILINE excipients list
DailyMed Link:	SELEGILINE at DailyMed

See drug prices for SELEGILINE

Recent Clinical Trials for SELEGILINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Ibadan	Phase 1/Phase 2
László Mangel	Phase 2
E-Group ICT Software Informatikai Zrt.	Phase 2

See all SELEGILINE clinical trials

Pharmacology for SELEGILINE

Drug Class	Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor
Mechanism of Action	Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors

Medical Subject Heading (MeSH) Categories for SELEGILINE

Antiparkinson Agents
Monoamine Oxidase Inhibitors
Neuroprotective Agents

Anatomical Therapeutic Chemical (ATC) Classes for SELEGILINE

N04BD	Monoamine oxidase B inhibitors
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for SELEGILINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecules	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	TABLET;ORAL	074565-001	Aug 2, 1996		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Kenton	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	TABLET;ORAL	074912-001	Apr 30, 1998		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Mlv	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	TABLET;ORAL	074672-001	Apr 1, 1997	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	ELDEPRYL	selegiline hydrochloride	CAPSULE;ORAL	020647-001	May 15, 1996		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SELEGILINE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-003	Feb 27, 2006	⤷ Sign Up	⤷ Sign Up
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-001	Feb 27, 2006	⤷ Sign Up	⤷ Sign Up
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-001	Feb 27, 2006	⤷ Sign Up	⤷ Sign Up
Somerset	EMSAM	selegiline	FILM, EXTENDED RELEASE;TRANSDERMAL	021336-002	Feb 27, 2006	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.